HaemaLogiX focus is the development and commercialisation of novel immuno-oncology and immune-therapies. HaemaLogiX is embarking on a program of several inter-related research and clincial development projects that will validate the antigen targets and products. We have a unique opportunity to develop effective treatments that improve the quality of life of patients suffering from blood cancers and autoimmune diseases.

Website: haemalogix.com

Employees: 5 - 9

HQ: N/A

Location: Eveleigh, NSW, US

Revenue: Not Available

Are you looking for contact information for HaemaLogiX Pty Ltd? ConnectPlex.ai is the ideal solution for all your lead generation needs! Our extensive database contains company information for millions of businesses worldwide, including HaemaLogiX Pty Ltd. You can easily find contact details for key decision-makers and professionals working at HaemaLogiX Pty Ltd. Our platform is designed to help you quickly locate the contact information you need, saving you time and effort. ConnectPlex.ai is the perfect tool for sales teams, marketers, and recruiters who need quick access to accurate contact information. Our platform is user-friendly, intuitive, and customizable to suit your needs. With ConnectPlex.ai, you can easily connect with the right people at HaemaLogiX Pty Ltd and other companies, enhancing your chances of success. Try ConnectPlex.ai today and discover how we can help you achieve your business goals!

HaemaLogiX Pty Ltd is a cutting-edge biotechnology company focused on developing and commercializing innovative immuno-oncology and immune-therapies. Based in Eveleigh, New South Wales, the company is committed to improving the quality of life for patients suffering from blood cancers and autoimmune diseases. With a strong mission and a talented team, HaemaLogiX is poised to make a significant impact in the healthcare industry. Led by Chairman and CEO Bryce Carmine and CFO | Company Secretary Dimitra Korkidas, HaemaLogiX is currently undertaking several inter-related research and clinical development projects. These projects aim to validate antigen targets and products, paving the way for effective treatments that can make a real difference in patients' lives. The company's focus on novel immuno-oncology and immune-therapies has the potential to revolutionize the way we approach cancer and autoimmune disease treatment. HaemaLogiX's commitment to innovation and patient-centric approach has earned them a reputation as a leader in the biotechnology industry. With a strong presence on LinkedIn and a website that provides valuable information on their research and development projects, the company is well-positioned to attract partnerships and investors who share their vision. As they continue to push the boundaries of medical research and development, HaemaLogiX is set to make a lasting impact on the healthcare industry and the lives of patients around the world.

HaemaLogiX is working on new treatments for blood cancers and autoimmune diseases. They want to make sure these treatments are safe and effective, so they're doing research and clinical trials to test them out. They're focusing on a few different projects that will help them figure out which antigens (substances that trigger an immune response) and products will work best. They're excited about the potential to improve patients' quality of life with these new treatments.